Antibody discovery is a long, costly, and complex process. LabGenius is reinventing that process by using its platform technology that combines AI with robotic systems capable of designing, conducting, and learning from its own experiments. Its platform not only has the potential to accelerate the drug discovery process but can generate high-performing molecules that likely would not have been found through conventional discovery methods. We spoke to James Field, founder and CEO of LabGenius, about the company’s use of generative AI to discover new therapeutic antibodies, its initial focus on immunotherapies, why he thinks the data the company is generating to train its AI system is a significant point of differentiation.
Overcoming Barriers to Delivering Large Molecules to the Brain
Developing Complex Therapies to Tackle Complex Diseases
How Solving a Problem with Genetic Medicines May Solve Another with Infectious Diseases
Boosting the Power of Dendritic Cancer Vaccines
Overcoming Resistance in Cancer with Chemistry
Teaching an Old Drug a New Trick to Prevent Lyme Disease
A New Class of Cell Therapies to Target Solid Tumors
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies
A Company Born from a Father Who Wore His Heart on His Sleeve
Using AI to Improve Burn Care
A Home for Biotech in the City that Never Sleeps
Biopharma R&D Growing Stronger
The Benefits of Having a Multitude of Cins
Making ADCs Smarter and Safer with a Simple Twist of Fate
Targeting a Natural Repair System to Restore Brain Health
Programing Cells in a Predictable and Scalable Way
Why DNA May Be the Data Storage Medium of the Future
Scouring Genetic Variation within Our Cells for Drug Targets
Correcting Gene Dysregulation to Treat Diseases
Using Technology to Regain Abilities after Spinal Cord Injury
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths